Statistics for Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks
Total visits
| views | |
|---|---|
| Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks | 31 |
Total visits per month
| views | |
|---|---|
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 1 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 1 |
| May 2025 | 0 |
File Visits
| views | |
|---|---|
| Jain_jac_remi.pdf | 53 |
| Jain_jac_remi.pdf(legacy) | 10 |
Top country views
| views | |
|---|---|
| United States | 19 |
| Belgium | 6 |
| Germany | 2 |
| Spain | 2 |
| Argentina | 1 |
| India | 1 |
Top city views
| views | |
|---|---|
| Menlo Park | 8 |
| Mountain View | 6 |
| Barcelona | 2 |
| Cupertino | 2 |
| Chennai | 1 |
| Fairfield | 1 |
| Suipacha | 1 |